StudyA.aids: ACTG 320 clinical trial data

In SurrogateSeq: Group Sequential Testing of a Treatment Effect Using a Surrogate Marker

ACTG 320 clinical trial data

Description

Primary outcome and surrogate marker measurements over time from the ACTG 320 clinical trial data

Usage

data("StudyA.aids")

Format

A list with 4 elements:

y1

the primary outcome in the treatment group in Study A; the primary outcome is defined as -1 times (log of RNA at 40 weeks - log of RNA at baseline) because a DECREASE in RNA is better

y0

the primary outcome in the control group in Study A

s1

a dataframe of the surrogate markers at different time points in the treatment group in Study A; the surrogate marker is change in CD4 cell count from baseline to 4 weeks (CD4_4weeks), 8 weeks (CD4_8weeks), 24 weeks (CD4_24weeks), and 40 weeks (CD4_40weeks). Note that higher values indicate increasing CD4 cell count which is "better".

s0

a dataframe of the surrogate markers at different time points in the control group in Study A

Examples

data(StudyA.aids)

SurrogateSeq documentation built on April 4, 2025, 12:27 a.m.